<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186261</url>
  </required_header>
  <id_info>
    <org_study_id>amshamaa</org_study_id>
    <nct_id>NCT03186261</nct_id>
  </id_info>
  <brief_title>Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique</brief_title>
  <official_title>Evaluation of the Antibacterial Effect of Nano Silver Fluoride Versus Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The teeth of the patients that meet inclusion criteria will be anesthetized, isolated&#xD;
           with a rubber dam.&#xD;
&#xD;
        -  Cavity opened using conventional high-speed rotary instruments.&#xD;
&#xD;
        -  The central cariogenic biomass and the superficial parts of the necrotic dentine will be&#xD;
           removed with round burs.&#xD;
&#xD;
        -  Caries lesion will be completely removed in the enamel/dentin junction.&#xD;
&#xD;
        -  The excavation procedure will be terminated as soon as the soft and wet dentine was&#xD;
           removed and the remaining tissue was leathery but not hard on exploring.&#xD;
&#xD;
        -  A dentinal sample will then be collected from the base of the cavity using sterile spoon&#xD;
           excavator as a baseline for bacteriological assessment.&#xD;
&#xD;
        -  Then, application of either intervention or control agent, another dentinal sample will&#xD;
           be collected using a sterile excavator and transferred into sterile tubes and&#xD;
           transferred to the laboratory for microbiological analysis.&#xD;
&#xD;
        -  Filling of the cavity with resin composite restoration.&#xD;
&#xD;
        -  All clinical procedures will be carried out at the same visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I.1. Study setting This clinical study will be held in the Clinic of Conservative Dentistry&#xD;
      Department, Faculty of Dentistry, Cairo University, Egypt. The researcher will bear ultimate&#xD;
      responsibility for all activities associated with the conduct of a research project including&#xD;
      recruitment of patients, explaining and performing the procedures to them.&#xD;
&#xD;
      II.4.a Excavation protocol:&#xD;
&#xD;
      The teeth of the patients that meet inclusion criteria will be anesthetized, isolated with a&#xD;
      rubber dam. Cavity opened using conventional high-speed rotary instruments. The central&#xD;
      cariogenic biomass and the superficial parts of the necrotic dentine will be removed with&#xD;
      round burs. Caries lesion will be completely removed in the enamel/dentin junction. The&#xD;
      excavation procedure will be terminated as soon as the soft and wet dentine was removed and&#xD;
      the remaining tissue was leathery but not hard on exploring. A dentinal sample will then be&#xD;
      collected from the base of the cavity using sterile spoon excavator as a baseline for&#xD;
      bacteriological assessment. Then, application of either intervention or control agent,&#xD;
      another dentinal sample will be collected using a sterile excavator and transferred into&#xD;
      sterile tubes and transferred to the laboratory for microbiological analysis.&#xD;
&#xD;
      II.4.b Assessment of Outcome:&#xD;
&#xD;
      Samples of carious dentine will be collected with sterile excavator before and after&#xD;
      application of intervention/control agent. The dentine samples will be transferred to sterile&#xD;
      container containing a 1mL thioglycollate medium used as a carrier, then this sterile&#xD;
      container will be kept in an ice box and taken to the microbiology laboratory for processing,&#xD;
      within an hour, by another examiner who is blinded to the type of agent applied after partial&#xD;
      caries removal. Samples will be vortexed for two minutes, decimally diluted and 0.1 ml will&#xD;
      be plated on Mitis Salivarius Bacitracin agar plates, these plates will be incubated&#xD;
      anaerobically for 48 hour at 37ºC then aerobically for 24 hour at room temperature. The&#xD;
      number of colonies will be expressed as colony-forming units (CFU/ml) compared before and&#xD;
      after application of the antibacterial agent.&#xD;
&#xD;
      II.5. Participant timeline:&#xD;
&#xD;
      All clinical procedures will be carried out at the same visit.&#xD;
&#xD;
      II.6. Sample size calculation:&#xD;
&#xD;
      The aim of this study is to evaluate the antibacterial action Nano Silver Fluoride solution&#xD;
      application in comparison to Chlorhexidine solution after partial caries removal in class I&#xD;
      carious permanent molar. Based on a previous study by Mohan et al. 20165, the expected&#xD;
      difference between two interventions is expected to be 2.1±2.2CFU/mL × 103. Using power 80%&#xD;
      and 5% significance level we will need to study 18 in each group to be able to reject the&#xD;
      null hypothesis that the population means of the experimental and control groups are equal.&#xD;
      This number is to be increased to 22 patients in each group to compensate for possible losses&#xD;
      during follow up. The sample size was calculated by PS program.&#xD;
&#xD;
      II.7. Recruitment:&#xD;
&#xD;
      Patients will be recruited from outpatient clinic of Conservative Dentistry Department in&#xD;
      Faculty of Dentistry, Cairo University; after explaining the benefits/risks from the&#xD;
      application of the interventions, then eligible patients will be recruited to fulfil the&#xD;
      eligibility criteria according to participant timeline.&#xD;
&#xD;
      II.8.a. Recruitment Strategy:&#xD;
&#xD;
      The patients will be subjected to full examination and diagnosis using dental charts. Once&#xD;
      the patients that are potentially eligible for this study are identified, they will be&#xD;
      contacted by the researcher who will explain the study and ascertains the patient's interest.&#xD;
      If interested, more detailed evaluations and preparations are made.&#xD;
&#xD;
      II.9. Randomization and assignment of interventions:&#xD;
&#xD;
      II.9.a. Allocation sequence generation:&#xD;
&#xD;
      The allocation sequence will be generated using (www.randomization.com).&#xD;
&#xD;
      II.9.b. Allocation concealment mechanism:&#xD;
&#xD;
      The randomization unit was the tooth, and the randomization procedure will be performed as&#xD;
      follows. A number corresponding to each treatment group will be printed on pieces of paper&#xD;
      and kept in dark containers. A paper will be selected from the container by a person other&#xD;
      than the operator, and the treatment indicated will be performed (intervention/control).&#xD;
      Blinding of the operator is not possible, because the color of intervention and control&#xD;
      solution is different. The operator is blinded until randomization into groups, to avoid&#xD;
      biases with regard to the application of antibacterial agent. Also, the examiner who will&#xD;
      carry the microbiological analysis of dentin samples will be blinded to the type of agent&#xD;
      applied during treatment. Finally, the treatment results will be assessed blindly by a&#xD;
      statistician.&#xD;
&#xD;
      II.9.c. Implementation:&#xD;
&#xD;
      Dr. Mai Mamdouh (co-supervisor) will perform the allocation sequence and assign the&#xD;
      participants to the intervention/Control treatment group.&#xD;
&#xD;
      II.9.d. Blinding:&#xD;
&#xD;
      The side to which interventions or control is assigned to will be recorded and all records of&#xD;
      all patients will be kept with the main supervisor. Blinding of the operator is not possible,&#xD;
      because the color of intervention and control solution is different. The operator is blinded&#xD;
      until randomization into groups, to avoid biases with regard to the application of&#xD;
      antibacterial agent. Also, the examiner who will carry the microbiological analysis of dentin&#xD;
      samples will be blinded to the type of agent applied during treatment. Finally, the treatment&#xD;
      results will be assessed blindly by a statistician.&#xD;
&#xD;
      II.10. Data collection methods:&#xD;
&#xD;
      *Baseline data collection: For every patient medical history, dental history and examination&#xD;
      charts will be filled by the operator. The report will be anonymous where patients identified&#xD;
      by their serial numbers (the first letter of the first and last name and date of birth) only&#xD;
      will be registered. Full detailed personal data of the patient will be written in separate&#xD;
      sheet having the patient's serial number for further contact with patient.&#xD;
&#xD;
      *Outcome data collection: The results will be converted into a table to facilitate the&#xD;
      description of the results. The microbiological analysis will be performed blindly in&#xD;
      relation to the type of solution applied after partial caries removal.&#xD;
&#xD;
      II.11.Data management:&#xD;
&#xD;
      The data will be entered and stored on a personal computer. Double data entry will be saved&#xD;
      on an external hard disc to prevent loss of data.&#xD;
&#xD;
      II.12. Statistical methods:&#xD;
&#xD;
      Data will be analyzed using IBM SPSS advanced statistics (Statistical Package for Social&#xD;
      Sciences), version 21 (SPSS Inc., Chicago, IL). Numerical data will be described as mean and&#xD;
      standard deviation or median and range. Categorical data will be explored for normality using&#xD;
      Kolmogrov-Smirnov test and Shapiro-Wilk test. Comparisons between two groups for normally&#xD;
      distributed numeric variables will be done using the Student's t-test while for non normally&#xD;
      distributed numeric variables will be done by Mann-Whitney test. Comparisons between&#xD;
      categorical variables will be performed using the chi square test. A p-value less than or&#xD;
      equal to 0.05 will be considered statistically significant. All tests will be two tailed.&#xD;
&#xD;
      II.13. Monitoring:&#xD;
&#xD;
      II.13.a. Data monitoring:&#xD;
&#xD;
      The main supervisor will monitor this study. His role is to monitor any risk of bias could be&#xD;
      done from participants, operator or assessors. Also to monitor blinding of the assessors and&#xD;
      patient safety, outstanding benefits or harms.&#xD;
&#xD;
      II.13.b. Harms:&#xD;
&#xD;
      The main supervisor should inform participants about the possible harms, if present.&#xD;
      Participants are allowed to contact the operator at moment through telephone. In case of&#xD;
      accidental pulp exposure during excavation , emergency access cavity and pulp extirpation&#xD;
      will be done by the operator and then the patient will be referred to Endodontic Department&#xD;
      clinic to complete the rool canal treatment.&#xD;
&#xD;
      II.13.c. Auditing:&#xD;
&#xD;
      In the present trial, auditing will be done by the main and co-supervisors to assure quality&#xD;
      of the research frequency procedures.&#xD;
&#xD;
      II.14. Ethics and dissemination&#xD;
&#xD;
      II.14.a. Research ethics approval:&#xD;
&#xD;
      Application forms for carrying out the clinical trial, checklist and informed consent of&#xD;
      Research Ethics Committee (REC) Faculty of Dentistry, Cairo University will be retrieved and&#xD;
      filled, then will be delivered for (REC) committee for approval. This is done to prevent any&#xD;
      ethical problems during the study or any harm for any of the participants.&#xD;
&#xD;
      II.14.b. Protocol amendments:&#xD;
&#xD;
      If a new protocol will be used a protocol amendment will be submitted; containing a new copy&#xD;
      of the new protocol and brief explanation about the differences between it and the previous&#xD;
      protocols. If there is a change in the existing protocol that affects safety of subjects,&#xD;
      investigation scope or scientific quality of the trial, an amendment containing a brief&#xD;
      explanation about the change will be submitted. If a new author will be added to accomplish&#xD;
      the study, an amendment including the investigator's data and qualifications to conduct the&#xD;
      investigation will be submitted to prevent ghost authorship.&#xD;
&#xD;
      II.14.c. Consent:&#xD;
&#xD;
      The operator (Ali Mostafa Shamaa) is responsible for admitting and signing the written&#xD;
      consents during the enrolment day.&#xD;
&#xD;
      II.15. Confidentiality:&#xD;
&#xD;
      Name, personal data and pictures of the participants will not appear on the protocol form and&#xD;
      will be maintained secured for 10 years after the trial. This is done for protection of&#xD;
      participants' privacy and civil rights.&#xD;
&#xD;
      II.16. Declaration of interests:&#xD;
&#xD;
      There is no conflict of interest, no funding or material supplying from any parties.&#xD;
&#xD;
      Access to final data will be allowed to the operator ,the main and co-supervisors of the&#xD;
      study who are not involved in assessment of the outcome.&#xD;
&#xD;
      II.18. Ancillary and post-trial care:&#xD;
&#xD;
      Patients will be followed up after the application after 3, 6 months.&#xD;
&#xD;
      II.19. Dissemination policy:&#xD;
&#xD;
      Full protocol will be published online in www.clinicaltrials.gov to avoid repetition and to&#xD;
      keep the integrity of the research work. Thesis will be discussed in front of judgment&#xD;
      committee. The study will be published to report the results of this clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">December 28, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial Count of Streptococus Mutans</measure>
    <time_frame>5 minutes on average between baseline and after application of the solution</time_frame>
    <description>Digital Colony Counter, Agar Diffusion test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Dental Caries</condition>
  <arm_group>
    <arm_group_label>Nano silver fluoride solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavity Cleanser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nano silver fluoride solution</intervention_name>
    <description>Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.</description>
    <arm_group_label>Nano silver fluoride solution</arm_group_label>
    <other_name>NSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavity Cleanser</intervention_name>
    <description>Moistens dentin surface after cavity preparation using a micro brush.</description>
    <arm_group_label>Cavity Cleanser</arm_group_label>
    <other_name>Chlorhexidine digluconate 2 % solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria of participants:&#xD;
&#xD;
               1. Not received antibiotic therapy since 1 month before sampling.&#xD;
&#xD;
               2. Good oral hygiene.&#xD;
&#xD;
               3. Co-operative patients approving the trial.&#xD;
&#xD;
          -  Inclusion Criteria of teeth:&#xD;
&#xD;
               1. Class I deep caries lesions in permanent molar (reaching ≥ 1/2 of the dentin on&#xD;
                  radiographic examination).&#xD;
&#xD;
               2. Absence of spontaneous pain; negative sensitivity to percussion; and absence of&#xD;
                  periapical lesions (radiographic examination).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria of participants:&#xD;
&#xD;
               1. Pregnancy.&#xD;
&#xD;
               2. Systemic disease or severe medical complications.&#xD;
&#xD;
               3. Heavy smoking.&#xD;
&#xD;
               4. Xerostomia.&#xD;
&#xD;
               5. Lack of compliance.&#xD;
&#xD;
          -  Exclusion criteria of teeth:&#xD;
&#xD;
               1. Class II caries lesion.&#xD;
&#xD;
               2. Shallow or enamel caries.&#xD;
&#xD;
               3. Cuspal loss or caries beneath the gingival margin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randa Hafez, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mai Mamdouh, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Dentistry, Cairo University.</name>
      <address>
        <city>Cairo</city>
        <zip>11311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mohan PV, Uloopi KS, Vinay C, Rao RC. In vivo comparison of cavity disinfection efficacy with APF gel, Propolis, Diode Laser, and 2% chlorhexidine in primary teeth. Contemp Clin Dent. 2016 Jan-Mar;7(1):45-50. doi: 10.4103/0976-237X.177110.</citation>
    <PMID>27041900</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <results_first_submitted>March 7, 2021</results_first_submitted>
  <results_first_submitted_qc>August 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2021</results_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>ali mostafa shamaa</investigator_full_name>
    <investigator_title>Principle Investigator, Dentist at Suez health directorate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03186261/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nano Silver Fluoride Solution</title>
          <description>Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Nano silver fluoride solution: Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.</description>
        </group>
        <group group_id="P2">
          <title>Cavity Cleanser</title>
          <description>Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Cavity Cleanser: Moistens dentin surface after cavity preparation using a micro brush.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nano Silver Fluoride Solution</title>
          <description>Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Nano silver fluoride solution: Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.</description>
        </group>
        <group group_id="B2">
          <title>Cavity Cleanser</title>
          <description>Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Cavity Cleanser: Moistens dentin surface after cavity preparation using a micro brush.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vital Permanent molar with deep occlusal carious lesion</title>
          <units>Teeth</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bacterial Count of Streptococus Mutans</title>
        <description>Digital Colony Counter, Agar Diffusion test</description>
        <time_frame>5 minutes on average between baseline and after application of the solution</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nano Silver Fluoride Solution</title>
            <description>Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Nano silver fluoride solution: Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.</description>
          </group>
          <group group_id="O2">
            <title>Cavity Cleanser</title>
            <description>Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Cavity Cleanser: Moistens dentin surface after cavity preparation using a micro brush.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Count of Streptococus Mutans</title>
          <description>Digital Colony Counter, Agar Diffusion test</description>
          <units>CFU/ml log10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.33"/>
                    <measurement group_id="O2" value="2.04" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After solution application</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.59"/>
                    <measurement group_id="O2" value="1.05" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nano Silver Fluoride Solution</title>
          <description>Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Nano silver fluoride solution: Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.</description>
        </group>
        <group group_id="E2">
          <title>Cavity Cleanser</title>
          <description>Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.&#xD;
Cavity Cleanser: Moistens dentin surface after cavity preparation using a micro brush.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ali Mostafa Shamaa</name_or_title>
      <organization>Faculty of Dentistry, Cairo University</organization>
      <phone>+201005276468</phone>
      <email>alishamaa@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

